Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Alpine Research Organization Inc

Neither a doctor nor a teaching hospital

Research payments

$1,048,106

600 payments

Through program year 2025, Alpine Research Organization Inc is reported as receiving $1,048,106 in research payments, across 600 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $403,303 90
2024 Research $246,137 78
2023 Research $46,190 17
2022 Research $42,125 86
2021 Research $57,775 120
2020 Research $95,867 110
2019 Research $156,710 99

Breakdown

Who paid Research payments · program years 2019–2025
  1. Indivior Inc. $543,902 156 payments
  2. Esperion Therapeutics, Inc. $123,103 208 payments
  3. Boehringer Ingelheim International GmbH $76,474 145 payments
  4. Boehringer Ingelheim Pharma GmbH & Co.KG $63,028 16 payments
  5. Amgen Inc. $56,623 6 payments
  6. Janssen Research & Development, LLC $41,957 4 payments
  7. Kowa Research Institute, Inc. $39,032 25 payments
  8. Tolmar, Inc. $35,780 15 payments
  9. Boston Scientific Corporation $28,770 19 payments
  10. AbbVie, Inc. $28,471 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase II Double Blind, Placebo Controlled, Randomised, Dose-Ranging Study to Assess the Safety and Efficacy of Indv-2000 Over 3 Months in Treatment Seeking Individuals With Opioid Use Disorder $497,214 23 payments
  2. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $123,103 208 payments
  3. Empagliflozin and heart failure (HFpEF) $120,121 119 payments
  4. FOURIER OLE (Ph 4) $44,187 4 payments
  5. A Phase IV Longitudinal Study of SUBLOCADE (SUBUTEX Prolonged Release) Clinical Outcomes in Adults With Opioid Use Disorder (Opioid Dependence) $42,574 116 payments
  6. Ranger II Sfa $28,770 19 payments
  7. K-877-302 $27,097 17 payments
  8. Tol-Clar-20024 $24,680 11 payments
  9. A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 $24,251 1 payment
  10. Empagliflozin and Heart failure (HFrEF) $19,381 42 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record